Nano vesicular lipid carriers of angiotensin II receptor blocker: Anti-hypertensive and skin toxicity study in focus

被引:27
|
作者
Ahad, Abdul [1 ]
Aqil, Mohd. [2 ]
Kohli, Kanchan [2 ]
Sultana, Yasmin [2 ]
Mujeeb, Mohd. [2 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia
[2] Jamia Hamdard, Fac Pharm, MB Rd, New Delhi 110062, India
关键词
anti-hypertensive; ethosomes; skin toxicity; valsartan; DRUG-DELIVERY SYSTEMS; VALSARTAN TRANSDERMAL GEL; IN-VITRO EVALUATION; PENETRATION ENHANCERS; PERMEATION; ETHOSOMES; OPTIMIZATION; HYPERTENSION; VESICLES; DESIGN;
D O I
10.3109/21691401.2015.1008509
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: Nanoethosomal carriers of valsartan have been previously prepared, characterized and optimized. A gel formulation of valsartan vesicular lipid carriers was composed of Carbopol((R)) (1% w/w), polyethylene glycol-400 (15% w/w) and triethanolamine (0.5% w/w). The influence of the valsartan nanoethosomal formulation developed on the blood pressure of experimental hypertensive rats, and its potential for skin irritation, are presented in this report. Materials and methods: The experimental rats were divided into three groups; the control group received no treatment (Group A). Group B was administered methyl prednisolone acetate (20 mg/kg/week) for two weeks (hypertensive control). Group C received methyl prednisolone acetate, followed by administration of the valsartan ethosomal formulation. The blood pressure of the rats was measured using a non-invasive rat blood pressure instrument based on the tail-cuff technique. The statistical analysis was performed using GraphPad InStat 3 software. Results and discussion: The treatment group showed a significant (P < 0.05) and constant fall in blood pressure, for up to 48 h. The valsartan ethosomal formulation was found to be effective, with a 34.11% reduction in blood pressure. The formulation's potential for skin irritation was assessed by the Draize irritation score test, which ruled out the possibility of any skin irritation caused by application of the formulation in rats. Conclusion: Our results suggest that nanoethosomes are efficient carriers for transdermal delivery of valsartan, for the management of hypertension.
引用
收藏
页码:1002 / 1007
页数:6
相关论文
共 33 条
  • [1] Carotid intima-media thickness and anti-hypertensive treatment: Focus on angiotensin II receptor blockers
    Cuspidi, Cesare
    Sala, Carla
    Tadic, Marijana
    Grassi, Guido
    Mancia, Giuseppe
    PHARMACOLOGICAL RESEARCH, 2018, 129 : 20 - 26
  • [2] The anti-hypertensive angiotensin II type I-receptor blocker (ARB) down-regalates the mRNA expewssion of PPAR gamma
    Nakanishi, K.
    Onuma, S.
    Nakayama, A.
    Hara, N.
    Nagai, Y.
    JOURNAL OF HYPERTENSION, 2008, 26 : S516 - S516
  • [3] Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers
    Choi, Won Joon
    Kim, Gi-Ae
    Park, Jaewon
    Jang, Sangmi
    Jung, Woo Jin
    Shim, Jae-Jun
    Park, Yewan
    Choi, Gwang Hyeon
    Kim, Jin-Wook
    Jeong, Sook-Hyang
    Jang, Eun Sun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (33)
  • [4] Biological evaluation of a novel angiotensin II AT1 receptor antagonist with anti-hypertensive and anti-tumor effects
    Da, Yajing
    Chen, Zhilong
    FRONTIERS OF CHEMICAL ENGINEERING, METALLURGICAL ENGINEERING AND MATERIALS II, 2013, 803 : 113 - 117
  • [5] Compatibility and anti-hypertensive effectiveness of angiotensin II-receptor type I blocker Olmesartan - Result of a prospective care studies with more than 20000 patients
    Wissmann, C.
    Limberg, R.
    Schmidt, A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (46) : S38 - S39
  • [6] Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker
    Hathout, Rania M.
    Elshafeey, Ahmed H.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 82 (02) : 230 - 240
  • [7] Comparison between angiotensin II receptor blocker and beta-blocker on blood pressure, hemodynamic, and lipid in hypertensive hypercholesterolemic patients treated with statin
    Prandin, M. G.
    Dormi, A.
    Veronesi, M.
    Bacchelli, S.
    Immordino, V.
    Ambrosioni, E.
    Borghi, C.
    JOURNAL OF HYPERTENSION, 2006, 24 : S37 - S37
  • [8] INCIDENCE AND PATTERN OF LIVER INJURY DURING ANTI-HYPERTENSIVE THERAPY WITH ANGIOTENSIN-II RECEPTOR BLOCKERS IN KOREAN PATIENTS
    Choi, Won Joon
    Jeong, Sook-Hyang
    Kim, Jin-Wook
    Jang, Eun Sun
    Choi, Gwang Hyeon
    Park, Jaewon
    Jang, Sangmi
    Jung, Woo Jin
    HEPATOLOGY, 2020, 72 : 719A - 719A
  • [9] Renal Protective Effect in Hypertensive Patients: The High Doses of Angiotensin II Receptor Blocker (HARB) Study
    Mitsuru Ohishi
    Takashi Takagi
    Norihisa Ito
    Yuji Tatara
    Norihiro Hayashi
    Atsushi Shiota
    Yoshihiro Iwamoto
    Tomohiro Katsuya
    Hiromi Rakugi
    Toshio Ogihara
    Hypertension Research, 2007, 30 : 1187 - 1192
  • [10] Renal protective effect in hypertensive patients: The high doses of angiotensin II receptor blocker (HARB) study
    Ohishi, Mitsuru
    Takagi, Takashi
    Ito, Norihisa
    Tatara, Yuji
    Hayashi, Norihiro
    Shiota, Atsushi
    Iwamoto, Yoshihiro
    Katsuya, Tornohiro
    Rakugi, Hiromi
    Ogihara, Toshio
    HYPERTENSION RESEARCH, 2007, 30 (12) : 1187 - 1192